OraSure Technologies (NASDAQ:OSUR) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a buy rating in a research note published on Wednesday morning.

Separately, Evercore ISI dropped their price objective on shares of OraSure Technologies from $7.00 to $6.50 and set an in-line rating on the stock in a research report on Thursday, April 4th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $6.38.

OraSure Technologies Price Performance

OSUR opened at $5.33 on Wednesday. The stock has a market capitalization of $407.80 million, a price-to-earnings ratio of 7.40 and a beta of 0.15. The business has a fifty day moving average price of $6.24 and a 200 day moving average price of $6.80. OraSure Technologies has a 12 month low of $4.38 and a 12 month high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The business had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. During the same period in the previous year, the company posted $0.21 earnings per share. The business’s revenue for the quarter was down 38.3% on a year-over-year basis. On average, research analysts anticipate that OraSure Technologies will post -0.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. AJOVista LLC purchased a new stake in OraSure Technologies during the fourth quarter worth approximately $39,000. Tocqueville Asset Management L.P. acquired a new position in shares of OraSure Technologies in the 3rd quarter valued at $75,000. Pathstone Family Office LLC purchased a new position in shares of OraSure Technologies in the 3rd quarter valued at $80,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of OraSure Technologies in the 4th quarter valued at $113,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in OraSure Technologies during the 4th quarter worth $115,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.